FRANKFURT, Oct. 29 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS; http://www.htdsmedical.com/) and its operating subsidiary Slavica Bio Chem, announces that it is targeting an EU based company, and has initiated talks that may involve a merger.
Hard to Treat Diseases Inc. (HTDS) and the newly targeted company, which does not wish to disclose its name at the present stage of negotiations, started talks about the possibilities for future cooperation and are in the process of reviewing initial documentation. The new company would give HTDS a new competitive edge on the pharmaceutical market, including providing HTDS with an increased revenue base.
The stem cell company focuses on research and storage of the umbilical cord stem cells, the only ethical source of stem cells in the world. Umbilical stem cells are more flexible in medical applications and possess 30% higher flexibility to match the patient than the bone marrow stem cells do. The company also serves its customers as an Umbilical Cord Blood Bank. The umbilical cord blood (UCB) is stored for treatment of leukemia, anaemia and other haematological conditions in the donor's family only.
This EU based Stem Cell Bank reports revenues in the range of Euro 3 million (Approximately $4.5 million USD) and profit range 35%. This new company sees profitable opportunity in cooperation with HTDS and Slavica Bio Chem, due to Slavica Bio Chem's low research and production costs and superior infrastructure provided by the Hard to Treat Diseases Inc.
The financial information and transaction details on revenues, assets and other will follow via usual newswire service.
The merger with the new company comes after the HTDS' long-term market research in the international markets. HTDS is the parent company of the Serbian Slavica Bio Chem research facility and Chinese Mellow Hope, the largest vaccine exporter in China. HTDS closely inspects the new research possibilities and business opportunities coming from this merger.
This merger is based on the targeted merger companies being able to meet and exceed both management and long-term shareholders reasonable expectations. The HTDS' management works in concert with its preferred shareholders and its M&A advisors on this merger and develops a complex preferred share exchange arrangement. The result will see HTDS' current (both common and preferred) share structure unchanged and undisturbed after the merger.
The targeted merger candidates would over time acquire the preferred shares and have an option to convert these preferred shares at a significantly higher strike price than what HTDS is currently trading at. The targeted merger candidates hope to benefit from this merger and increase their revenues.
A research report of the stem cell project was filed with Pink Sheets www.pinksheets.com on Nov 26 under the "Research Tab". The company will shortly make announcements on its H1N1 sales progress and the Mind Up cancer project.
To be included in HTDS' email database for press releases and industry updates, please subscribe at or opt in with your email address at this link http://www.minamargroup.com/updates/.
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
SOURCE Hard to Treat Diseases
|SOURCE Hard to Treat Diseases|
Copyright©2009 PR Newswire.
All rights reserved